Safety, Tolerability, PK and PD of ADX-850 in Participants with Hypertension

Recruiting Status: Active, not recruiting Age: 18 – 65 Years Old The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in patients with hypertension. Learn More

The release as fetched from its publisher. adarx.com ↗